I am the Director of Barts Cancer Institute. My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
Cancers are composed of both tumour and stromal compartments. We are interested in understanding the molecular basis of how the tumour stroma contributes to tumour growth, therapy resistance and spread, in various solid tumours including lung cancers, pancreatic cancer and melanoma.
My clinical research interests include tissue banking, clinical trials, innovative surgical techniques, epidemiology, meta-analysis and patient care pathways. My translational research interests include pancreatic cancer stroma and tumour-stroma cross-talk including cell signalling, adhesion, metastasis and invasion.
I study the biology of tumour invasion with a particular focus on the roles of the adhesion molecules expressed on the cell surface that mediate this process. Our group concentrates on the study of integrins that are the principal family of adhesion molecules that mediate the interaction between cells and the extracellular matrix.
My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs. My group is currently examining the role of the PKN kinases in malignant progression.
My research interests lie in the area of translational bioinformatics. Current research projects are focused in high-throughput data analysis, integration with clinical data, databases and software development, particularly for pancreatic cancer and breast cancer.
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
We are interested in understanding the cellular and molecular mechanisms that promote cancer cell plasticity and adaptation of tumour cells in metastatic niches and under therapeutic pressure.
The research in our team is focused on the development of novel treatment strategies to target prostate and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells but leave normal cells unharmed.
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
My focus is detailed translational trials in pancreatic cancer. I work with scientists within the BCI in crosscutting themes targeting the tumour microenvironment, with approaches including immune therapies, stem cell, stromal and vascular targeting.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
The primary focus of my research is to establish a platform for a neo-antigens-based vaccine for triple-negative breast cancer and pancreatic cancer.
My research is focused on combining modulation of the tumour microenvironment with chimeric antigen receptor T cell therapy in order to therapeutically target pancreatic ductal adenocarcinoma.
My work focuses on the global analysis of miRNA in pancreatic cancer and developing miRNA biomarkers for early detection of this malignancy.
My research is focused on investigating the crosstalk between immune cell subsets in the tumour microenvironment in pancreatic ductal adenocarcinoma.
My research is focused in understanding the tumour-stroma interactions in pancreatic cancer and the identification of potential biomarkers.
My work focuses on c-Met signalling on endosomes in pancreatic cancer, and to evaluate how it can be exploited to benefit pancreatic cancer patients.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
I am investigating the use of virotherapeutic strategies for treating pancreatic cancer. Our research focuses on the use of modified oncolytic Vaccinia viruses armed with immune-modulatory genes such as cytokines to create a novel treatment for tumours.
My work focuses on the influence of PKN2 on the immune-microenvironment, and the invasion and metastasis of pancreatic ductal adenocarcinoma in vivo, using murine models.
My research is focused on understanding how integrins help cancer cells invade and metastasise, as well as how we can use integrins as biomarkers of disease and therapeutic targets.
My research is focussed on the disturbed epigenomic landscape within pancreatic tumours.
In particular, I investigate the bi-directional epigenetic reprogramming between the tumour microenvironment and pancreatic cancer stem cells that leads to cooperative tumour outgrowth.
I work on developing preclinical models of chimeric antigen receptors for cell therapy of pancreatic ductal adenocarcinoma.
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.
My research is focused on understanding the role of contractility in pancreatic cancer.
My work focuses on cancer immunotherapy using oncolytic viruses (vaccinia virus and adenovirus) and engineered T cells. I will also be looking at the state of immune cells in the tumour microenvironment.
My research focus is on cancer immunotherapy using oncolytic viruses (vaccinia virus) and engineered T cells.